Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
12/2003
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002101394A3 Screening method which uses bnpi and dnpi
12/04/2003WO2002094186A3 Urazole compounds useful as anti-inflammatory agents
12/04/2003WO2002078747A8 Pregabalin lactose conjugates
12/04/2003WO2002073208A3 Anti-epileptogenic agents
12/04/2003WO2002068397A8 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
12/04/2003WO2002043774A3 Compositions and therapeutical use of polynucleotides encoding tcrs
12/04/2003US20030225450 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003US20030225288 Small organic compounds to modulate chemokine receptor activity; treating psoriasis, autoimmune diseases, multiple sclerosis, graft rejection, infectious diseases; anti-allergen, -arthritic, -inflammatory, carcinogenic agents
12/04/2003US20030225287 Synthesis of chiral 2-alkyl amino acids
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225271 Compounds useful as reversible inhibitors of cysteine proteases
12/04/2003US20030225270 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis
12/04/2003US20030225269 Inhibitors of interleukin-1beta converting enzyme
12/04/2003US20030225160 Esterified hydroxytyrosol; 2-(3,4-dihydroxyphenyl)ethyl acetate for example
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225111 Use of a quinazoline derivative such as 1-(2,6-dichloro-phenyl)-3-(7-(3-morpholinopropoxy)quinazolin-4-yl) urea to produce an antiangiogenic and/or vascular permeability reducing effect
12/04/2003US20030225108 Process for making substituted pyrazoles
12/04/2003US20030225106 Prophylaxis and treatment of angiogenesis mediated diseases such as cancer
12/04/2003US20030225103 Method of using diketopiperazines and composition containing them
12/04/2003US20030225094 E.g, 4-(2-((6R,12aR)-6-benzo(1,3)dioxol-5-yl-1,4-dioxo -3,4,6,7,12,12a-hexahydro-1H-pyrazino-(1',2':1,6)pyrido(3,4-b) indol-2-yl)ethyl)-benzenesulfonamide; inhibitors of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase
12/04/2003US20030225093 Cyclic gmp-specific phosphodiesterase inhibitors
12/04/2003US20030225092 E.g., 6-Benzo(1,3)dioxol-5-yl-10-hydroxy-2-methyl-2,3,6,7,12, 12a-hexa-hydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase
12/04/2003US20030225090 Oxindole derivatives
12/04/2003US20030225089 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
12/04/2003US20030225084 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others.
12/04/2003US20030225082 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225063 Treating autoimmune diseases mediated by cathepsin S
12/04/2003US20030225062 Treating autoimmune diseases mediated by cathepsin S
12/04/2003US20030225061 Protease inhibitors
12/04/2003US20030225060 Acylated piperidine derivatives as melanocortin-4 receptor agonists
12/04/2003US20030225059 Cyclohexyl derivatives and their use as therapeutic agents
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225053 N-arylcarboxamides of fused ring systems including naphthalenes, benzothiophenes, benzofurans and indoles
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030224987 Binding to formyl peptide receptor or formyl peptide receptor-like 1
12/04/2003US20030224487 Novel cytokine zcytor17 ligand
12/04/2003US20030224413 Comprises polynucleotides coding restriction fragment length polymorphism for use in identifying, characterizing and treatment of blood, respiratory, tumor and nervous system disorders
12/04/2003US20030224076 Anti-inflammatory and chemopreventive composition
12/04/2003US20030224073 Cinnamomi and poria composition, method to prepare same and uses thereof
12/04/2003US20030224057 Continuous method for preparing pharmaceutical granules
12/04/2003US20030224014 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
12/04/2003US20030224008 Novel uses for anti-malarial therapeutic agents
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003US20030223969 Method of modulating inflammatory response
12/04/2003US20030223938 Relates to nanoparticles comprised of a carrier, particularly polymerized lipids, and ligands displayed on the carrier, wherein the ligands form a polyvalent binding unit that is effective to produce a specific interaction between the
12/04/2003CA2784937A1 Ccr9 inhibitors and methods of use thereof
12/04/2003CA2493902A1 Decoy composition for treating and preventing inflammatory disease
12/04/2003CA2490542A1 Fas peptide mimetics and uses thereof
12/04/2003CA2487732A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487246A1 Novel uses of cephaibols
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2487017A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486966A1 Substituted quinazolinone compounds
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486716A1 Compositions and their uses for alleviating pain
12/04/2003CA2486564A1 Acetamides and benzamides that are useful in treating sexual dysfunction
12/04/2003CA2486376A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003CA2486187A1 Kinase inhibitors
12/04/2003CA2485184A1 Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
12/04/2003CA2485166A1 Substituted pyrimidinone and pyridinone compounds
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484656A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003CA2484288A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2480756A1 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
12/03/2003EP1367051A2 Inhibitors of tumor necrosis factor alpha
12/03/2003EP1366773A1 Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same
12/03/2003EP1366772A1 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same
12/03/2003EP1366771A2 Use of the neurotoxic compnent of botulinum toxins as a medicament
12/03/2003EP1366770A2 Use of botulinum toxin for treating muscle-associated pain
12/03/2003EP1366763A1 Hydroxy diphenyl ether compounds as anti-inflammatory agents
12/03/2003EP1366673A2 Carob product based antiinflammatory or chemopreventative agent
12/03/2003EP1366165A2 G-protein coupled receptors
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366161A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof
12/03/2003EP1366150A2 Use of protein histidine phosphatase
12/03/2003EP1366146A2 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366078A2 Ige receptor antagonists
12/03/2003EP1366064A1 Tumour targeting prodrugs activated by metallo matrixproteinases
12/03/2003EP1366050A2 Condensed pyrazindione derivatives as pde inhibitors
12/03/2003EP1366049A2 Pirazino[1'2':1,6]pyrido[3,4-b]indole derivatives
12/03/2003EP1366047A1 Thiazole compounds as tgf-beta inhibitors
12/03/2003EP1366039A1 Piperazinylcarbonylquinolines and -isoquinolines
12/03/2003EP1366036A2 Compounds having activity as inhibitors of cytochrome p450rai
12/03/2003EP1366028A1 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
12/03/2003EP1366024A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
12/03/2003EP1366020A1 Urea derivatives having vanilloid receptor (vr1) antagonist activity
12/03/2003EP1366018A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
1 ... 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 ... 1272